New research demonstrates 2.3 point reduction in hba1c for dario digital health users with baseline hba1c greater than 9 points

Retrospective cohort study presented at the american diabetes association 83rd scientific sessions analyzed real-world data of dario users against matched controls to demonstrate a greater reduction when compared to non-users who achieve a 1.8 point reduction with the usual standard of care new york , june 26, 2023 /prnewswire/ -- dariohealth corp. (nasdaq: drio) ("dario" or the "company"), a leader in the global digital health market, announced today the presentation of research at the american diabetes association 83rd scientific sessions (the "scientific sessions") demonstrating significant reductions in hba1c for dario users compared to non-users. the study was conducted by sanofi u.s. ("sanofi") under its strategic agreement with dario.
DRIO Ratings Summary
DRIO Quant Ranking